New Phase II Data Bolster vTv Therapeutics’ Glucokinase Activator Aspirations
Could Product Succeed Where SGLT2 Inhibitors Failed?
The future for glucokinase activation is looking brighter after fresh data on vTv’s oral adjunct to insulin therapy in type 1 diabetes.
You may also be interested in...
Public Company Edition: It has been almost a month since a biopharma firm launched an IPO in the US, but special purpose acquisition corporations continue to take drug makers public, including Alvotech and Aerami. Outside the US, MaaT closed an IPO in Paris and BeiGene priced a Shanghai offering.
Lexicon labelled Sanofi’s unilateral decision to exit their alliance ‘invalid’ and said the French drugmaker was thus ‘in breach of contract’. Sanofi said its move was triggered by Phase III trial data studying the dual SGLT1 and SGLT2 inhibitor in type-2 diabetes.
The UK pharma said the FDA had issued a complete response letter, declining its application for using Farxiga in the new T1D indication. Analysts suspect worries over diabetic ketoacidosis risk lie behind the rejection.